Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling

BACKGROUND: Cisplatin resistance remains a major clinical obstacle to the successful treatment of non-small cell lung cancer (NSCLC). Scribble contributes to ROS-induced inflammation and cisplatin-elevated toxic reactive oxygen species (ROS) promotes cell death. However, it is unknown whether and ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Na, Song, Lele, Xu, Yi, Zhang, Longfu, Wu, Yanjun, Guo, Jingyu, Ji, Weiwei, Li, Li, Zhao, Jingya, Zhang, Xin, Zhan, Lixing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796531/
https://www.ncbi.nlm.nih.gov/pubmed/31495720
http://dx.doi.org/10.1016/j.ebiom.2019.08.057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6796531/
https://www.ncbi.nlm.nih.gov/pubmed/31495720
http://dx.doi.org/10.1016/j.ebiom.2019.08.057

Ejemplares similares